E. Weidekamm

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

Johannes Sch�ller, Jim Cassidy, Étienne Dumont et al. · Cancer Chemotherapy and Pharmacology · 2000 · 666 citations

Oncology, Chemoprevention Strategy, Gastrointestinal Oncology +10

Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

Anne Schmitt‐Hoffmann, Brigitte Roos, M. Heep et al. · Antimicrobial Agents and Chemotherapy · 2005 · 169 citations · Full text

Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.

Bruno Reigner, Jaco J. Verweij, Luc Dirix et al. · PubMed · 1998 · 161 citations

Nutrition, Chemoprevention Strategy, Food Intake +17

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.

Chris Twelves, Rob Glynne‐Jones, Jim Cassidy et al. · PubMed · 1999 · 158 citations

Hepatic Dysfunction, Chemoprevention Strategy, Pathology +22

Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers

Anne Schmitt‐Hoffmann, Brigitte Roos, J. Maares et al. · Antimicrobial Agents and Chemotherapy · 2005 · 139 citations · Full text